Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response

Cancer Res (2019) 79 (13_Supplement): CT195.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review

Ariadna Juarez-Garcia
Ruchika Sharma
Matthias Hunger
Sheena Kayaniyil
John R. Penrod
Christos Chouaïd

Lung Cancer (2022) 166: 205.

Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options

Jose Luis Leal
Thomas John

Clinical Lung Cancer (2022) 23 (8): 643.

Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer – predictors of response and impact of previous radiotherapy

Åsa Kristina Öjlert
Daniel Nebdal
Marius Lund-Iversen
Renée Åstrøm Ellefsen
Odd Terje Brustugun
Jon Michael Gran
Ann Rita Halvorsen
Åslaug Helland

Acta Oncologica (2021) 60 (2): 149.

Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells

Rui Yang
Susu Shen
Cheng Gong
Xin Wang
Fang Luo
Fengyan Luo
Yang Lei
Zili Wang
Shasha Xu
Qian Ni
Yan Xue
Zhen Fu
Liang Zeng
Lijuan Fang
Yongxiang Yan
Jing Zhang
Lu Gan
Jizu Yi
Pengfei Zhou

Frontiers in Immunology (2021) 12

Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne

A. Scherpereel
M. Pérol
C. Gauvain
A. Cortot
E. Giroux-Leprieur

Revue des Maladies Respiratoires Actualités (2020) 12 (2): 2S185.

Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy

Jose Carlos Benitez
Jordi Remon
Benjamin Besse

Clinical Cancer Research (2020) 26 (19): 5068.

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept

Thierry Berghmans
Valérie Durieux
Lizza E. L. Hendriks
Anne-Marie Dingemans

Frontiers in Medicine (2020) 7

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?

Sanjay Popat
Christian Grohé
Jesus Corral
Martin Reck
Silvia Novello
Maya Gottfried
Dejan Radonjic
Rolf Kaiser

Lung Cancer (2020) 144: 76.

Factors related to rapid progression of non‐small cell lung cancer in Chinese patients treated using single‐agent immune checkpoint inhibitor treatment

Liang Zhang
Lianwei Bai
Xianhong Liu
Ying Liu
Shuang Li
Jingjing Liu
Shuang Zhang
Changliang Yang
Xiubao Ren
Ying Cheng

Thoracic Cancer (2020) 11 (5): 1170.

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

D. Planchard
N. Reinmuth
S. Orlov
J.R. Fischer
S. Sugawara
S. Mandziuk
D. Marquez-Medina
S. Novello
Y. Takeda
R. Soo
K. Park
M. McCleod
S.L. Geater
M. Powell
R. May
U. Scheuring
P. Stockman
D. Kowalski

Annals of Oncology (2020) 31 (5): 609.

Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients

K. K. Laktionov
V. V. Breder
D. I. Yudin
K. A. Sarantseva
L. V. Laktionova
M. S. Ardzinba
E. V. Reutova
A. V. Egorova

Medical Council (2019) (19): 22.